PAHC icon

Phibro Animal Health

39.62 USD
-1.57
3.81%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
39.40
-0.22
0.56%
1 day
-3.81%
5 days
0%
1 month
33.49%
3 months
61.65%
6 months
79.6%
Year to date
91.12%
1 year
86.8%
5 years
117.81%
10 years
14.31%
 

About: Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Employees: 2,475

0
Funds holding %
of 7,462 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

48% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 21

20% more capital invested

Capital invested by funds: $434M [Q1] → $519M (+$84.8M) [Q2]

4% more funds holding

Funds holding: 183 [Q1] → 191 (+8) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

0.09% more ownership

Funds ownership: 99.62% [Q1] → 99.71% (+0.09%) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$26
-34% downside
Avg. target
$29
-26% downside
High target
$35
-12% downside

3 analyst ratings

positive
33%
neutral
33%
negative
33%
B of A Securities
Derik De Bruin
$27
Underperform
Maintained
29 Aug 2025
JP Morgan
Ekaterina Knyazkova
$35
Overweight
Upgraded
7 Jul 2025
Morgan Stanley
Erin Wright
$26
Equal-Weight
Maintained
25 Jun 2025

Financial journalist opinion

Based on 25 articles about PAHC published over the past 30 days

Positive
Zacks Investment Research
3 days ago
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?
Positive
Zacks Investment Research
3 days ago
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Positive
Zacks Investment Research
3 days ago
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
Neutral
Seeking Alpha
3 days ago
Phibro Animal Health Corporation (PAHC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Phibro Animal Health Corporation (NASDAQ:PAHC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Glenn David - Chief Financial Officer Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Hi. Good afternoon, everyone.
Phibro Animal Health Corporation (PAHC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Positive
Zacks Investment Research
9 days ago
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Positive
Zacks Investment Research
9 days ago
Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"
Phibro (PAHC) could produce exceptional returns because of its solid growth attributes.
Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
10 days ago
Why Phibro Animal Health (PAHC) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Phibro Animal Health (PAHC) is a Top Growth Stock for the Long-Term
Neutral
Business Wire
10 days ago
Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A repl.
Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference
Positive
Seeking Alpha
11 days ago
Phibro Animal Health: Zoetis Growth, Valuation Still Attractive
Phibro Animal Health Corporation's Zoetis MFA acquisition has revitalized its overall growth. Animal Health is now around 75% of their total sales, and its integration should be finalized by Q4 2025. Post-integration, PAHC believes Zoetis MFAs will normalize to flat growth. But, Vaccines and Nutritional Specialties should continue growing at double digits. PAHC's Phibro Forward initiative is also adding new efficiencies in procurement, commercial, and process improvements.
Phibro Animal Health: Zoetis Growth, Valuation Still Attractive
Positive
Zacks Investment Research
12 days ago
Unlocking Phibro (PAHC) International Revenues: Trends, Surprises, and Prospects
Explore Phibro's (PAHC) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Unlocking Phibro (PAHC) International Revenues: Trends, Surprises, and Prospects
Charts implemented using Lightweight Charts™